tetano
Editor, Senior Moderator
Clin Exp Pediatr
. 2021 Jun 30.
doi: 10.3345/cep.2021.00717. Online ahead of print.
Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia
Young Shil Park[SUP] 1 [/SUP]
Affiliations
Abstract
The development of vaccines against severe acute respiratory syndrome coronavirus 2, which features high mortality and morbidity rates, has progressed at an unprecedented rate, and vaccines are currently in use worldwide. Thrombotic events after vaccination are accompanied by thrombocytopenia, and this issue was recently termed vaccine-induced immune thrombotic thrombocytopenia. This manuscript describes recently published guidelines and other related issues and demonstrates characteristic cases.
Keywords: SARS-CoV-2 vaccine; TTS; Thrombocytopenia; Thrombosis; VITT.
Young Shil Park[SUP] 1 [/SUP]
Affiliations
Abstract
The development of vaccines against severe acute respiratory syndrome coronavirus 2, which features high mortality and morbidity rates, has progressed at an unprecedented rate, and vaccines are currently in use worldwide. Thrombotic events after vaccination are accompanied by thrombocytopenia, and this issue was recently termed vaccine-induced immune thrombotic thrombocytopenia. This manuscript describes recently published guidelines and other related issues and demonstrates characteristic cases.
Keywords: SARS-CoV-2 vaccine; TTS; Thrombocytopenia; Thrombosis; VITT.
. 2021 Jun 30.
doi: 10.3345/cep.2021.00717. Online ahead of print.
Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia
Young Shil Park[SUP] 1 [/SUP]
Affiliations
- PMID: 34237213
- DOI: 10.3345/cep.2021.00717
Abstract
The development of vaccines against severe acute respiratory syndrome coronavirus 2, which features high mortality and morbidity rates, has progressed at an unprecedented rate, and vaccines are currently in use worldwide. Thrombotic events after vaccination are accompanied by thrombocytopenia, and this issue was recently termed vaccine-induced immune thrombotic thrombocytopenia. This manuscript describes recently published guidelines and other related issues and demonstrates characteristic cases.
Keywords: SARS-CoV-2 vaccine; TTS; Thrombocytopenia; Thrombosis; VITT.
Young Shil Park[SUP] 1 [/SUP]
Affiliations
- PMID: 34237213
- DOI: 10.3345/cep.2021.00717
Abstract
The development of vaccines against severe acute respiratory syndrome coronavirus 2, which features high mortality and morbidity rates, has progressed at an unprecedented rate, and vaccines are currently in use worldwide. Thrombotic events after vaccination are accompanied by thrombocytopenia, and this issue was recently termed vaccine-induced immune thrombotic thrombocytopenia. This manuscript describes recently published guidelines and other related issues and demonstrates characteristic cases.
Keywords: SARS-CoV-2 vaccine; TTS; Thrombocytopenia; Thrombosis; VITT.